BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Chubb
Fish and Richardson
Cipla
Deloitte
Federal Trade Commission
Chinese Patent Office
Johnson and Johnson
Boehringer Ingelheim
Express Scripts

Generated: January 22, 2018

DrugPatentWatch Database Preview

SANOFI AVENTIS US Company Profile

« Back to Dashboard

Summary for SANOFI AVENTIS US
International Patents:1042
US Patents:57
Tradenames:113
Ingredients:93
NDAs:136

Drugs and US Patents for SANOFI AVENTIS US

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us AVAPRO irbesartan TABLET;ORAL 020757-002 Sep 30, 1997 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us HYGROTON chlorthalidone TABLET;ORAL 012283-003 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us NEGGRAM nalidixic acid TABLET;ORAL 014214-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us APIDRA SOLOSTAR insulin glulisine recombinant INJECTABLE;SUBCUTANEOUS 021629-003 Feb 24, 2009 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-008 Jun 2, 2000 AP RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us MULTAQ dronedarone hydrochloride TABLET;ORAL 022425-001 Jul 1, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sanofi Aventis Us HYDROXYSTILBAMIDINE ISETHIONATE hydroxystilbamidine isethionate INJECTABLE;INJECTION 009166-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us VANOBID candicidin TABLET;VAGINAL 061613-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us PENETREX enoxacin TABLET;ORAL 019616-004 Dec 31, 1991 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us LANTUS SOLOSTAR insulin glargine recombinant INJECTABLE;INJECTION 021081-002 Apr 27, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for SANOFI AVENTIS US

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-005 Mar 27, 1998 ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us SKELID tiludronate disodium TABLET;ORAL 020707-001 Mar 7, 1997 ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-002 Jan 30, 1998 ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us CHILDREN'S ALLEGRA ALLERGY fexofenadine hydrochloride TABLET;ORAL 020872-005 Jan 24, 2011 ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us SKELID tiludronate disodium TABLET;ORAL 020707-001 Mar 7, 1997 ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us AVAPRO irbesartan TABLET;ORAL 020757-001 Sep 30, 1997 ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us TORNALATE bitolterol mesylate SOLUTION;INHALATION 019548-001 Feb 19, 1992 ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us CHILDREN'S ALLEGRA HIVES fexofenadine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021909-003 Jan 24, 2011 ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;IV (INFUSION) 021759-003 Nov 17, 2006 ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us TAXOTERE docetaxel INJECTABLE;INJECTION 020449-003 Aug 3, 2010 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for SANOFI AVENTIS US drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Transdermal System 7 mg/24 hrs, 14 mg/24 hrs, and 21 mg/24 hrs ➤ Subscribe 5/30/2014
➤ Subscribe Tablets 400 mg ➤ Subscribe 7/1/2013
➤ Subscribe Injection 5 mg/mL, 40 mL vial ➤ Subscribe 3/23/2011
➤ Subscribe Oral Suspension 30 mg/5 mL ➤ Subscribe 1/25/2010
➤ Subscribe Injection 40 mg/mL, 0.5 mL and 2 mL vials ➤ Subscribe 6/30/2009
➤ Subscribe Tablets 300 mg ➤ Subscribe 3/4/2009
➤ Subscribe Injection 200 mg/40 mL ➤ Subscribe 7/16/2007
➤ Subscribe Injection 5 mg/mL, 10 mL and 20 mL vials ➤ Subscribe 2/9/2007
➤ Subscribe For Injection 50 mg/vial and 100 mg/vial ➤ Subscribe 2/9/2007
➤ Subscribe Injection 100 mg/mL, 3 mL vials ➤ Subscribe 12/7/2006
➤ Subscribe Tablets 300 mg/25 mg ➤ Subscribe 6/6/2006
➤ Subscribe Extended-release Tablets 6.25 mg ➤ Subscribe 2/24/2006
➤ Subscribe Extended-release Tablets 12.5 mg ➤ Subscribe 1/19/2006
➤ Subscribe Tablets 150 mg/12.5 mg and 300 mg/12.5 mg ➤ Subscribe 11/10/2004
➤ Subscribe Tablets 75 mg, 150 mg and 300 mg ➤ Subscribe 5/25/2004
Premature patent expirations for SANOFI AVENTIS US

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Subscribe ➤ Subscribe

Non-Orange Book US Patents for SANOFI AVENTIS US

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,888,750 Pen-type injector ➤ Subscribe
7,122,206 Aqueous-based pharmaceutical composition ➤ Subscribe
6,593,482 Methods for preparing new taxoids and pharmaceutical compositions containing them ➤ Subscribe
6,100,404 Erythromycin compounds ➤ Subscribe
7,850,662 Drive mechanisms suitable for use in drug delivery devices ➤ Subscribe
7,622,136 Transparent transdermal nicotine delivery devices ➤ Subscribe
7,935,088 Drive mechanisms suitable for use in drug delivery devices ➤ Subscribe
8,663,175 Drive mechanisms suitable for use in drug delivery devices ➤ Subscribe
7,205,276 Zinc-free and low-zinc insulin preparations having improved stability ➤ Subscribe
6,331,635 Taxoids, their preparation and pharmaceutical compositions containing them ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for SANOFI AVENTIS US Drugs

Supplementary Protection Certificates for SANOFI AVENTIS US Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0041 France ➤ Subscribe PRODUCT NAME: ERTAPENEM SODIUM; REGISTRATION NO/DATE: EU/1/02/216/001 20020418
0596 Netherlands ➤ Subscribe PRODUCT NAME: INSULINE DEGLUDEC; NATIONAL REGISTRATION NO/DATE: EU/1/12/807/004 20130123; FIRST REGISTRATION: EU EU/1/12/807/001 20130123
C0031 France ➤ Subscribe PRODUCT NAME: DRONEDARONE; REGISTRATION NO/DATE IN FRANCE: EU/1/09/591/001 DU 20091126; REGISTRATION NO/DATE AT EEC: EU/1/09/591/001-004 DU 20091126
2014004,C1381356 Lithuania ➤ Subscribe PRODUCT NAME: TERIFLUNOMIDUM; REGISTRATION NO/DATE: EU/1/13/838/001-005 20130826
14/058 Ireland ➤ Subscribe PRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REGISTRATION NO/DATE: EU/1/14/924/001-002 20140516
2010000029 Germany ➤ Subscribe PRODUCT NAME: DRONEDARON ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE DAS HYDROCHLORIDSALZ; REGISTRATION NO/DATE: EU/1/09/591/001-004 20091126
673 Luxembourg ➤ Subscribe 91673, EXPIRES: 20230619
C0022 France ➤ Subscribe PRODUCT NAME: MONTELUKAST SODIUM; REGISTRATION NO/DATE IN FRANCE: NL 23 133 DU 19980320; REGISTRATION NO/DATE AT EEC: 13 651 DU 19970825
2209800/01 Switzerland ➤ Subscribe PRODUCT NAME: INSULIN DEGLUDEC + LIRAGLUTIDE; REGISTRATION NO/DATE: SWISSMEDIC 65041 12.09.2014
2011 00026 Denmark ➤ Subscribe PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Covington
Boehringer Ingelheim
Healthtrust
QuintilesIMS
Cipla
Johnson and Johnson
Argus Health
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot